No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Guiyang Xintian Pharmaceutical Co.,Ltd. is a Chinese company dedicated to the research, development, production, and commercialization of traditional Chinese medicines (TCMs) for a wide range of ailments. Its product offerings include various pharmaceutical formulations such as hard capsules, gels, mixtures, granules, and tablets. These medicines are specifically designed to treat diverse medical conditions, including antitumor applications, gynecological issues, urinary tract problems, breast and thyroid disorders, blood-related illnesses, heat-related syndromes, oral health complaints, common colds, and cardiovascular diseases. The company was founded in 1995 and is headquartered in Guiyang, China.
www.gyxtyy.comNo one on the platform currently holds 002873.SZ.
No tracked institution reports a position in 002873.SZ as of their last filing.
No one on the platform has traded 002873.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.6% | — | — | — | ||
| Rev. Growth % | -12.6% | -0.0% | ||||
| Profit Margin % | 1.2% | 7.3% | 8.4% | |||
| Free Cash Flow Margin % | 4.3% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $669M | +6.0% | $0.15 | $0.15–$0.15 | — | 1 |
| 2027 | $696M | +4.0% | $0.18 | $0.18–$0.18 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002873.SZGuiyang Xintian Pharmaceutical Co.,Ltd. | $7.98 | +0.25% | $1.9B | — |
| 000518.SZJiangsu Sihuan Bioengineering Co., Ltd | $3.79 | -0.00% | $3.9B | — |
| 002566.SZJilin Jian Yisheng Pharmaceutical Co., Ltd. | $6.86 | +1.03% | $2.3B | — |
| 002898.SZSailong Pharmaceutical Group Co., Ltd. | $0.37 | -2.63% | $65M | — |
| 300254.SZShanXi C&Y Pharmaceutical Group Co., Ltd. | $8.45 | +1.56% | $2.2B | — |
| 300519.SZZhejiang Xinguang Pharmaceutical Co., Ltd. |
Source: Financial Modeling Prep · peers by sector/industry
| $13.65 |
| +0.15% |
| $2.2B |
| — |
| 300583.SZShandong Sito Bio-technology Co., Ltd. | $12.66 | +0.48% | $2.4B | — |